BioNexus Gene Lab Corp. Equity Method Investment, Realized Gain (Loss) on Disposal
BioNexus Gene Lab Corp. (BGLC) reported Equity Method Investment, Realized Gain (Loss) on Disposal of $27.20 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-14.
Financial Statements › Income Statement › Other Income
us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal · last filed 2026-04-14
- BioNexus Gene Lab Corp. equity method investment, realized gain (loss) on disposal for the quarter ending 2025-12-31 was -$346.00, a 110.45% decline year-over-year.
- BioNexus Gene Lab Corp. equity method investment, realized gain (loss) on disposal for the quarter ending 2024-12-31 was $3.31K.
- BioNexus Gene Lab Corp. equity method investment, realized gain (loss) on disposal for the quarter ending 2024-09-30 was $20.80K.
- BioNexus Gene Lab Corp. equity method investment, realized gain (loss) on disposal for fiscal 2025 was $27.20K, a 29.18% decline from fiscal 2024.
- BioNexus Gene Lab Corp. equity method investment, realized gain (loss) on disposal for fiscal 2024 was $38.41K.
| Period end | Equity Method Investment, Realized Gain (Loss) on Disposal 3 month | Equity Method Investment, Realized Gain (Loss) on Disposal 6 month | Equity Method Investment, Realized Gain (Loss) on Disposal 9 month | Equity Method Investment, Realized Gain (Loss) on Disposal 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$346.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $27.20K 10-K · filed 2026-04-14 | ||
| 2025-09-30 | $27.55K 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | $3.31K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $24.11K derived: sum of 2 quarters · filed 2026-04-14 | $38.41K 10-K · filed 2026-04-14 | |
| 2024-09-30 | $20.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $35.10K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $14.30K 10-Q · filed 2025-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |